サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1678825

プレシジョンメディシンの世界市場 (2025年～2033年)

Global Precision Medicine Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
プレシジョンメディシンの世界市場 (2025年～2033年)
出版日: 2025年03月11日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

プレシジョンメディシン（精密医療）の世界市場は、2024年に1,737億米ドルに達し、2033年には5,507億4,000万米ドルに達すると予測され、2025年から2033年の予測期間中に13.4％のCAGRで成長すると予測されています。

プレシジョンメディシンは、患者一人ひとりの特性を考慮することで、より個別化された効果的な治療を提供することを目的とした高度な医療アプローチです。これらの特性には、遺伝的体質、ライフスタイルの選択、環境の影響などの要因が含まれます。特定の疾患を持つすべての患者に対して標準化された治療法を用いることが多い従来の医療とは異なり、プレシジョンメディシンは個人に合わせて治療法を調整し、その人特有のニーズや生物学的プロファイルに適した治療法を保証します。

市場力学：

促進要因と抑制要因

ゲノミクスの技術的進歩

ゲノミクスの技術的進歩は、世界のプレシジョンメディシン市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。次世代シーケンシング（NGS）、CRISPRベースの遺伝子編集、シングルセルゲノミクスなどのゲノミクスの技術進歩は、より正確な疾患診断、標的治療、個別化治療戦略を可能にすることで、プレシジョンメディシンに革命をもたらしました。

これらの技術革新により、遺伝子検査はより身近で安価なものとなり、AIと機械学習は予測モデリング、創薬、バイオマーカー同定を強化するために統合されつつあります。

個人の遺伝子プロファイルに基づく個別化治療の開発は、薬物応答を最適化するファーマコゲノミクスとともに、世界のプレシジョンメディシン市場に大きな影響を与えています。例えば、2024年9月、ImpriMed社は、人工知能（AI）を使って患者のがんが異なる薬剤にどのように反応するかを予測する新しいがん治療予測技術を発表しました。このAI主導の技術は、薬効に関する個別化された予測を提供することで、腫瘍学治療を改善するように設計されており、医師がより多くの情報に基づいた治療決定を下すのに役立ちます。

また、2023年6月、ダートマス大学はプレシジョン・ヘルス・人工知能（AI）センターを立ち上げました。同センターの目標は、AIや機械学習などの最先端ツールとプレシジョンメディシンを統合し、医療に革命をもたらし、よりパーソナライズされた治療法を生み出すことです。これらすべての要因が、世界のプレシジョンメディシン市場に需要をもたらしています。

高い治療・診断費用

治療や診断にかかる高額な費用は、プレシジョンメディシンの世界の普及を阻む大きな障壁となっており、特に低所得者層ではその利用が制限されています。個別化医療に不可欠な次世代シーケンシング（NGS）や高度なゲノム検査などの技術は依然として高価であり、全ゲノムシーケンスは患者1人当たり数千ドルもかかります。

さらに、CRISPRベースの遺伝子編集や標的がん治療などの個別化治療の開発には、高額な研究、臨床試験、規制当局の承認が必要となります。CAR-T細胞療法は、画期的ながん治療法ですが、患者一人当たり37万3,000ドルもの費用がかかるため、特に発展途上国や十分な保険に加入していない多くの患者には手が届きません。同様に、嚢胞性線維症やデュシェンヌ型筋ジストロフィーのような希少疾患のゲノム検査も法外な費用がかかることがあり、先進国であっても保険がこれらの費用を完全にサポートしないことがあります。このような経済的障壁がプレシジョンメディシンの普及を妨げ、世界の医療システムを変革する可能性を制限しています。このように、上記の要因が世界のプレシジョンメディシン市場の潜在的成長を制限している可能性があります。

目次

第1章 分析手法と分析範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • ゲノミクスにおける技術的進歩
      • 研究開発（R&D）への投資
    • 抑制要因
      • 治療と診断にかかる高額な費用
      • データ統合と標準化の問題
    • 機会
      • 個別化医療の需要増大
    • 影響分析

第5章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
  • 新たな先駆者と主要企業
  • 最大の売上を誇るブランドを確立したリーダー
  • 確立された製品を持つ市場リーダー
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の研究
  • 規制と償還の情勢
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析：ベストケース・ベースケース・ワーストケースの予測
  • 価格分析と価格市場力学
  • キーオピニオンリーダー (KOL)

第6章 製品種類別

  • 治療薬
    • 低分子医薬品
    • 生物製剤
    • 細胞・遺伝子治療
    • その他
  • 診断
    • 遺伝子検査
    • コンパニオン診断
    • バイオマーカーベース検査
    • その他

第7章 技術別

  • ゲノミクス
  • 次世代シーケンシング（NGS）
  • 人工知能（AI）・ビッグデータ分析
  • その他

第8章 用途別

  • 腫瘍
  • 神経症
  • 心臓病
  • 感染症
  • 免疫疾患・炎症
  • その他

第9章 エンドユーザー別

  • 製薬企業
  • 診断検査室
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ地域
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
    • 企業概要
    • 製品ポートフォリオ
      • 製品説明
      • 製品の主要業績評価指標（KPI）
      • 製品販売の実績・予測
      • 製品販売量
    • 財務概要
      • 企業の収益
      • 収益シェア：地域別
      • 収益予測
    • 主な動向
      • 企業合併・買収 (M&A)
      • 主な製品開発活動
      • 規制当局の承認等
    • SWOT分析
  • Thermo Fisher Scientific Inc.
  • AstraZeneca
  • Pfizer Inc.
  • GSK plc
  • Biogen
  • Bristol-Myers Squibb Company
  • Abbott
  • Merck & Co., Inc.
  • BGI
  • Illumina, Inc.
  • QIAGEN
  • Novartis AG

第13章 付録

目次
Product Code: PH39

The global precision medicine market reached US$ 173.70 billion in 2024 and is expected to reach US$ 550.74 billion by 2033, growing at a CAGR of 13.4 % during the forecast period of 2025-2033.

Precision medicine is an advanced healthcare approach that aims to provide more personalized and effective treatments by considering the unique characteristics of each patient. These characteristics include factors like genetic makeup, lifestyle choices, and environmental influences. Unlike traditional medicine, which often uses a standardized treatment for all patients with a particular disease, precision medicine tailors therapies to the individual, ensuring they are more suited to the person's specific needs and biological profile.

Market Dynamics: Drivers & Restraints

Technological Advancements in Genomics

The technological advancements in genomics are significantly driving the growth of the global precision medicine market and are expected to drive it throughout the market forecast period. Technological advancements in genomics, such as next-generation sequencing (NGS), CRISPR-based gene editing, and single-cell genomics, have revolutionized precision medicine by enabling more accurate disease diagnoses, targeted therapies, and personalized treatment strategies.

These innovations have made genetic testing more accessible and affordable, while AI and machine learning are being integrated to enhance predictive modeling, drug discovery, and biomarker identification.

The development of personalized therapies based on an individual's genetic profile, along with pharmacogenomics optimizing drug responses, has significantly impacted the global precision medicine market. For instance, in September 2024, ImpriMed unveiled a new cancer treatment forecast technology that uses artificial intelligence (AI) to predict how a patient's cancer will respond to different drugs. This AI-driven technology is designed to improve oncology treatment by providing personalized predictions of drug efficacy, which can help doctors make more informed treatment decisions.

Also, in June 2023, Dartmouth launched the Center for Precision Health and Artificial Intelligence (AI), which is designed to enhance the use of biomedical data and advanced technologies to improve healthcare outcomes. The center's goal is to integrate cutting-edge tools like AI and machine learning with precision medicine to revolutionize healthcare and create more personalized treatment options. All these factors demand the global precision medicine market.

High Costs of Treatment and Diagnostics

The high costs of treatment and diagnostics are a significant barrier to the global adoption of precision medicine, limiting its accessibility, especially in low-income regions. Technologies like next-generation sequencing (NGS) and advanced genomic tests, which are essential for personalized medicine, remain expensive, with whole-genome sequencing costing thousands of dollars per patient.

Additionally, the development of personalized therapies, such as CRISPR-based gene editing and targeted cancer treatments, involves costly research, clinical trials, and regulatory approvals. A clear example is CAR-T cell therapy, a breakthrough cancer treatment that can cost up to $373,000 per patient, making it inaccessible for many, particularly in developing countries or for those without adequate insurance. Similarly, genomic tests for rare diseases, such as cystic fibrosis and Duchenne muscular dystrophy, can also be prohibitively expensive, and even in developed countries, insurance coverage may not fully support these costs. These financial barriers hinder the widespread adoption of precision medicine, limiting its potential to transform global healthcare systems. Thus, the above factors could be limiting the global precision medicine market's potential growth.

Segment Analysis

The global precision medicine market is segmented based on product type, technology, application, end-user, and region.

Product Type:

The therapeutics segment is expected to dominate the global precision medicine market share

The therapeutics segment holds a major portion of the global precision medicine market share and is expected to continue to hold a significant portion of the global precision medicine market share during the forecast period. Therapeutics in precision medicine are personalized treatments designed to address the specific genetic, molecular, or cellular factors of a disease, offering more effective and less toxic alternatives to traditional one-size-fits-all treatments. Small molecule drugs, which are chemically synthesized compounds, target specific molecular pathways or receptors involved in diseases, such as genetic mutations or abnormal proteins identified through genetic testing.

Targeted cancer therapies focus on mutations like EGFR in non-small cell lung cancer. Biologics, which are large molecules derived from living organisms, include monoclonal antibodies, vaccines, and therapeutic proteins. These are used to treat diseases like cancer, autoimmune disorders, and genetic conditions by targeting specific biomarkers or immune responses, with trastuzumab (Herceptin) for HER2-positive breast cancer being a notable example.

Cell and gene therapies are cutting-edge treatments that modify cells or genes to treat or cure diseases. For instance, in December 2024, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation (RPDD) for its investigational drug, relutrigine, in the treatment of Dravet syndrome. This designation is a significant milestone in the development of relutrigine for this rare and severe pediatric disorder. These factors have solidified the segment's position in the global precision medicine market.

Geographical Analysis

North America is expected to hold a significant position in the global precision medicine market share

North America holds a substantial position in the global precision medicine market and is expected to hold most of the market share. The North America precision medicine market is growing rapidly, fueled by advancements in genomics, biotechnology, and a strong healthcare infrastructure. Innovations like next-generation sequencing (NGS) and CRISPR gene editing have revolutionized the ability to analyze genetic data and create targeted therapies, enabling more precise treatments for complex diseases such as cancer, cardiovascular conditions, and neurological disorders. With a robust healthcare system and increasing awareness among patients and providers, personalized treatments are becoming more common, especially in oncology.

Government support, such as the U.S. Precision Medicine Initiative, alongside investments from pharmaceutical and biotechnology companies, has further accelerated market growth. Additionally, rising consumer awareness, favorable reimbursement policies, and a growing demand for genetic testing and personalized treatments are helping drive the expansion of precision medicine in North America.

The strategic partnerships and collaborations among major players also contribute to the region's market growth. Several companies in the region enter into strategic relations to expand their business. For instance, in January 2024, BIOS Health entered into a partnership with the city of Bakersfield in Kern County, California, and the Kern Venture Group to establish a precision medicine center. This center will focus on neural clinical trials and research and development (R&D), utilizing BIOS Health's adaptive dosing technology. Thus, the above factors are consolidating the region's position as a dominant force in the global precision medicine market.

Competitive Landscape

The major global players in the precision medicine market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., AstraZeneca, Pfizer Inc., GSK plc, Biogen, Bristol-Myers Squibb Company, Abbott, Merck & Co., Inc., BGI, Illumina, Inc., QIAGEN, and Novartis AG, among others.

Key Developments

  • In January 2025, Caris Life Sciences announced a strategic collaboration with Ontada to advance oncology research and increase the adoption of precision medicine in cancer care. This partnership combines Caris Life Sciences' expertise in precision oncology and genetic testing with Ontada's capabilities in health data solutions. The collaboration aims to accelerate cancer research and improve the application of personalized treatments for cancer patients.
  • In December 2024, Aster DM Healthcare launched Precision Oncology, an initiative designed to offer data-driven, personalized cancer care. This new approach leverages cutting-edge genetic and molecular information to create individualized treatment plans for cancer patients, aiming to improve outcomes and reduce the side effects of treatment.
  • In October 2024, the National Institutes of Health (NIH) launched a proof-of-concept clinical trial to test new treatment combinations targeting specific genetic changes in cancer cells in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This initiative is a part of the NIH's larger effort to advance precision medicine in cancer care.
  • In June 2023, the National Cancer Institute (NCI) launched a large-scale precision medicine cancer initiative aimed at testing the effectiveness of treating adults and children with new drug combinations designed to target specific tumor alterations. This initiative represents a significant advancement in cancer treatment, focusing on customizing therapies based on the genetic and molecular characteristics of a patient's tumor rather than relying on standard, one-size-fits-all approaches.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global precision medicine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements in Genomics
      • 4.1.1.2. Investments in Research and Development (R&D)
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Treatment and Diagnostics
      • 4.1.2.2. Data Integration and Standardization Issues
    • 4.1.3. Opportunity
      • 4.1.3.1. Growing Demand for Personalized Healthcare
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
  • 5.2. Emerging Pioneers and Prominent Players
  • 5.3. Established leaders with largest selling Brand
  • 5.4. Market leaders with established Product
  • 5.5. CXO Perspectives
  • 5.6. Latest Developments and Breakthroughs
  • 5.7. Case Studies/Ongoing Research
  • 5.8. Regulatory and Reimbursement Landscape
  • 5.9. North America
  • 5.10. Europe
  • 5.11. Asia Pacific
  • 5.12. Latin America
  • 5.13. Middle East & Africa
  • 5.14. Porter's Five Force Analysis
  • 5.15. Supply Chain Analysis
  • 5.16. Patent Analysis
  • 5.17. SWOT Analysis
  • 5.18. Unmet Needs and Gaps
  • 5.19. Recommended Strategies for Market Entry and Expansion
  • 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.21. Pricing Analysis and Price Dynamics
  • 5.22. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index By Product Type
  • 6.2. Therapeutics*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Small Molecule Drugs
    • 6.2.4. Biologics
    • 6.2.5. Cell and Gene Therapy
    • 6.2.6. Others
  • 6.3. Diagnostics
    • 6.3.1. Genetic Tests
    • 6.3.2. Companion Diagnostics
    • 6.3.3. Biomarker-Based Tests
    • 6.3.4. Others

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index By Technology
  • 7.2. Genomics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Next-Generation Sequencing (NGS)
  • 7.4. Artificial Intelligence (AI) & Big Data Analytics
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index By Application
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Neurology
  • 8.4. Cardiology
  • 8.5. Infectious Diseases
  • 8.6. Immunology & Inflammation
  • 8.7. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Laboratories
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. Latin America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Mexico
      • 10.4.7.2. Brazil
      • 10.4.7.3. Argentina
      • 10.4.7.4. Rest of Latin America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Thermo Fisher Scientific Inc.
  • 12.3. AstraZeneca
  • 12.4. Pfizer Inc.
  • 12.5. GSK plc
  • 12.6. Biogen
  • 12.7. Bristol-Myers Squibb Company
  • 12.8. Abbott
  • 12.9. Merck & Co., Inc.
  • 12.10. BGI
  • 12.11. Illumina, Inc.
  • 12.12. QIAGEN
  • 12.13. Novartis AG

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us